



Living Cell Technologies Limited

ACN: 104 028 042
ASX: LCT
OTCQX: LVCLY

ASX ANNOUNCEMENT

Half yearly report ended 31 December 2020

Sydney, Australia & Auckland, New Zealand, 25 February 2021 – Living Cell Technologies Limited today announced the half yearly report for the six months ended 31 December 2020. The report is attached.

The consolidated loss after tax for the half year amounted to \$643,439 (2019 loss: \$225,985).

Research and development cost are significantly down on last year due to COVID-19 and the resulting lockdowns affecting the projects undertaken in conjunction with the University of Auckland. The migraine project milestones were renegotiated due to the delays caused by the lockdowns and the obesity project was put on hold, while resources were focused on progressing the migraine project.

Governance costs are in line with last year, with savings made by holding the November AGM online. As well as being a cost-effective approach, it allowed a greater proportion of shareholders to join the meeting than would be able to attend an in-person AGM.

In January this year, Dr Ken Taylor signalled his intention to retire as CEO in July. Dr Taylor joined LCT as CEO in February 2014 and was appointed to the board in August 2018, after a prominent international career in business and academia. He will work with the board and management over the coming months to assist the company with the transition to its next phase.

The net assets of the consolidated group have decreased by \$599,913 from \$2,878,354 at 30 June 2020 to \$2,278,441 as at 31 December 2020. This was attributed to the continued Research and Development expenditure on the milestone payments for the obesity and migraine novel peptide treatment projects.

Authorised for release by the Board of Living Cell Technologies Limited.

– Ends –

For further information: www.lctglobal.com

At the Company: Ken Taylor Chief Executive Mobile: +64 21 796 000 ktaylor@lctglobal.com	Media Contact: Rachael Joel Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 403 504 rachaelj@botica.co.nz
---	---

About Living Cell Technologies

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

As well as NTCELL, LCT is also advancing research collaborations with the University of Auckland to identify products that are candidates for out licensing to global pharmaceutical companies. Projects that have been initiated target obesity and migraine where the lead product candidates utilise patented novel peptide synthetic chemistry technology.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter.

Forward-looking statements

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.